The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up

Haematologica

Volumn 94, Issue 2, 2009, Pages 205-212

  Palandri, Francesca ^a   Castagnetti, Fausto ^a   Alimena, Giuliana ^b   Testoni, Nicoletta ^a   Breccia, Massimo ^b   Luatti, Simona ^a   Rege Cambrin, Giovanna ^c   Stagno, Fabio ^d   Specchia, Giorgina ^e   Martino, Bruno ^f   Levato, Luciano ^d   Merante, Serena ^g   Liberati, Anna Maria ^h   Pane, Fabrizio ⁱ   Saglio, Giuseppe ^c   Alberti, Daniele ^j   Martinelli, Giovanni ^a   Baccarani, Michele ^a   Rosti, Gianantonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Department of Hematology ^*  (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h POLICLINICO MONTELUCE   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j Novartis Pharma   (Italy)

more..

Author keywords

Accelerated phase; Chronic myeloid leukemia; Imatinib; Long term results

Indexed keywords

ALPHA INTERFERON; BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ERUPTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 59549084574     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13529     Document Type: Article

References (30)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-501.
2. Kelliher M, McLaughlin J, Witte O, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA 1990;87:6649-53.
3. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia: current status and investigational options. Science 1990;274:824-30.
4. Kantarjian HM, Dixon D, Keating M, Talpaz M, Andersson B, Beran M, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
5. Karanas A, Silver R. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 1968;32:445-9.
6. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
7. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006;106:1306-15.
8. Majlis A, Smith T, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996;14:196-203.
9. Druker B, Tamura S, Buchdunger E Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996;2:561-6.
10. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998;4:1661-72.
11. Sacchi S, Kantarjian HM, O'Brien S, Cortes J, Rios MB, Giles FJ, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999;86:2632-41.
12. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
13. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
14. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
15. Sureda A, Carrasco M, de Miguel M, Martínez JA, Conde E, Sanz MA, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88:1213-20.
16. Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA, et al. Four years of follow-up of 1027 patients with late chronic phase (LCP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104;23.
17. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002;8:2167-76.
18. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
19. Kantarjian HM, Giles F, O'Brien S Giralt S, Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer 2000;89:1647-58.
20. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992;772-8.
21. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70.
24. Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome. GIMEMA Working Party on CML. Haematologica 2008;93:770-4.
25. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, et al. GIMEMA Working Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008;26:106-11.
26. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
27. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9.
28. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50.
29. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
30. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006;108:1421-3.